Assessment of health complications associated with methadone use in the general population in France: incidence of hospitalizations and deaths and the role of drug-drug interactions (METHALICA)

First published: 12/07/2024 Last updated: 12/07/2024





Administrative details

PURI

https://redirect.ema.europa.eu/resource/1000000250

EU PAS number

EUPAS1000000250

Study ID

1000000250

DARWIN EU® study

No

Study countries

France

Study status

Planned

Research institution and networks

Institutions



Contact details

Study institution contact

Thomas Soeiro

Study contact

thomas.soeiro@ap-hm.fr

Primary lead investigator

Thomas Soeiro

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

03/11/2023

Study start date

Planned:

01/01/2024

Date of final study report

Planned:

31/12/2025

Sources of funding

National competent authority (NCAs)

More details on funding

EPI-PHARE/ANSM

Study protocol

SOEIRO - projet METHALICA - document_scientifique_aap2023.pdf(981.56 KB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Safety study (incl. comparative)

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name METHADONE

Anatomical Therapeutic Chemical (ATC) code

(N02AC) Diphenylpropylamine derivatives (N07BC02) methadone

Data management

Data sources

Data source(s)

Système National des Données de Santé (French national health system main database)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

Yes